Ambrisentan Patent Expiration
Ambrisentan is used for treating pulmonary arterial hypertension (PAH) in combination with tadalafil by inhibiting endothelin receptors. It was first introduced by Gilead Sciences Inc
Ambrisentan Patents
Given below is the list of patents protecting Ambrisentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Letairis | US9549926 | Compositions and methods of treating pulmonary hypertension | Oct 14, 2031 | Gilead |
| Letairis | US8377933 | Method for treating a pulmonary hypertension condition | Dec 11, 2027 | Gilead |
| Letairis | US9474752 | Method for treating a pulmonary hypertension condition | Dec 11, 2027 | Gilead |
| Letairis | USRE42462 | Carboxylic acid derivatives, their preparation and use |
Jul 29, 2018
(Expired) | Gilead |
| Letairis | US5840722 | Use of carboxylic acid derivatives as drugs |
Nov 24, 2015
(Expired) | Gilead |
| Letairis | US7109205 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US7601730 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US8349843 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US5703017 | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec 30, 2014
(Expired) | Gilead |
Ambrisentan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ambrisentan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | Actelion | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities | Assistance Publique - Hôpitaux de Paris | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |
| Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome | Noorik Biopharmaceuticals AG | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE2 |